Literature DB >> 8280612

Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.

K P Hoyes1, J B Porter.   

Abstract

The interactions of iron chelators with intracellular iron pools have been examined by measuring the subcellular distribution of radiolabelled desferrioxamine (DFO) and the orally active hydroxypyridinone (HPO) chelator 1,2-diethyl-3-hydroxypyridin-4-one (CP94), as well as the ability of these chelators to modify the subcellular distribution of 59Fe delivered by the receptor mediated endocytosis of transferrin. K562 cells were pulsed with 59Fe transferrin and challenged with DFO or CP94 (100 microM IBE) for 20 or 240 min and then subjected to subcellular fractionation. At 20 min there was a significant decrease (P < 0.05) in both lysosomal/particulate 59Fe (75% of control) and cytosolic 59Fe ferritin (50% of control) in cells incubated with CP94, unlike cells treated with DFO where no decrease was observed. By 240 min, in addition to the above, 59Fe accumulation was significantly decreased in the nuclear, mitochondrial, and low molecular weight cytosolic fractions with CP94 (P < 0.05). With DFO a significant decrease in 59Fe in only the lysosomal/particulate and cytosolic ferritin compartments was observed at 240 min (P < 0.05). At this time, however, there was a significant accumulation of both cytosolic low molecular weight 59Fe and cytosolic DFO. The relatively rapid decrease of 59Fe within intracellular compartments seen with CP94 compared to DFO was paralleled by a significantly higher accumulation of CP94 than DFO in nuclear, lysosomal/particulate and low molecular weight cytosolic compartments at 20 min (P < 0.05). These results suggest that transferrin derived endosomal iron may be chelated by HPOs, unlike DFO, due to their faster uptake into these organelles. The more rapid access of HPOs than DFO to certain intracellular iron pools may explain the greater possibility of HPOs to inhibit proliferation of cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280612     DOI: 10.1111/j.1365-2141.1993.tb03184.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

Authors:  Yoshihiko Ichikawa; Mohsen Ghanefar; Marina Bayeva; Rongxue Wu; Arineh Khechaduri; Sathyamangla V Naga Prasad; R Kannan Mutharasan; Tejaswitha Jairaj Naik; Hossein Ardehali
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  Conjugation of hydroxyethyl starch to desferrioxamine (DFO) modulates the dual role of DFO in Yersinia enterocolitica infection.

Authors:  S Schubert; I B Autenrieth
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

Authors:  Ashutosh Lal; John Porter; Nancy Sweeters; Vivian Ng; Patricia Evans; Lynne Neumayr; Gregory Kurio; Paul Harmatz; Elliott Vichinsky
Journal:  Blood Cells Mol Dis       Date:  2012-11-11       Impact factor: 3.039

4.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

5.  Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes.

Authors:  R D Abeysinghe; B L Ellis; J B Porter
Journal:  Eur J Nucl Med       Date:  1994-10

6.  UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

Authors:  Lie Michael George Limenta; Totsapol Jirasomprasert; Jeeranut Tankanitlert; Saovaros Svasti; Prapin Wilairat; Udom Chantharaksri; Suthat Fucharoen; Noppawan Phumala Morales
Journal:  Br J Clin Pharmacol       Date:  2008-03-03       Impact factor: 4.335

7.  Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Authors:  Evangelia Vlachodimitropoulou; Yu-Lin Chen; Maciej Garbowski; Pimpisid Koonyosying; Bethan Psaila; Martha Sola-Visner; Nichola Cooper; Robert Hider; John Porter
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

8.  Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents.

Authors:  A Curnow; B W McIlroy; M J Postle-Hacon; J B Porter; A J MacRobert; S G Bown
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

9.  Tryparedoxin peroxidase-deficiency commits trypanosomes to ferroptosis-type cell death.

Authors:  Marta Bogacz; R Luise Krauth-Siegel
Journal:  Elife       Date:  2018-07-26       Impact factor: 8.140

10.  An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.

Authors:  Lizette Anayo; Anette Magnussen; Alexis Perry; Mark Wood; Alison Curnow
Journal:  Lasers Surg Med       Date:  2018-03-31       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.